Cyteir Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | −$48.2M | −$42.3M | −$20.9M |
| Net income | −$46.1M | −$42.1M | −$20.8M |
| Total assets | $153.2M | $195.4M | $13.7M |
| Total liabilities | $6.9M | $8.1M | $4.4M |
| Equity | $146.3M | $187.3M | −$48.0M |
| EPS (diluted) | $-1.31 | $-2.16 | — |
| Shares out. | 35.4M | 35.2M | 2.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −31.5%
- Return on assets
- −30.1%
- Return on capital (ROCE)
- −32.6%
- Liabilities / assets
- 4.5%
- Debt / equity
- 0.05×
- Book value / share
- $4.13
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- 23.22safe
- Accruals / assets
- −2.3%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Modified shareholder rightsMar 20, 2024
- Delisting / listing-standard notice · Other material eventMar 7, 2024
- Director / officer changeDec 27, 2023
- Director / officer changeDec 7, 2023
- Director / officer changeDec 5, 2023
- Shareholder voteNov 17, 2023
- Other material eventOct 12, 2023
- Entered a material agreementOct 5, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.